NEW YORK, NY / ACCESSWIRE / December 26, 2017 / WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that it has initiated Corporate Profile coverage on Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"). WallStreet Research™ is ranked Number One on the Google, Yahoo, and Bing search engines for both small- and micro-cap research with a global following. A WSR Corporate Profile Report on Jaguar Health, Inc., together with additional information about WallStreet Research™, is available at www.WallStreetResearch.org. The WSR Corporate Profile highlights the Company's recent accomplishments and growth plans for 2018 and beyond.
Jaguar is a commercial stage natural-products pharmaceuticals company focused on developing and commercializing sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company's goal is to become a leading provider of products that address unmet gastrointestinal health needs for the human market as well both the companion and production animal markets.
The Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceutical products from plants used traditionally in rainforest areas. Napo has launched its FDA-approved human drug product, Mytesi® (crofelemer), which is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy (ART). Mytesi® is a first-in-class anti-secretory agent and the first oral drug approved by the FDA under botanical guidance. Mytesi® is in development by Napo for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and as a second-generation anti-secretory agent for use in Cholera patients.
Jaguar has received Minor Use in a Major Species designation from the FDA for its animal drug product candidate, Canalevia™, for the indication of chemotherapy-induced diarrhea in dogs. The Company has also completed submission to the FDA of all required major technical sections for conditional approval for Canalevia™.
Equilevia™ is Jaguar's non-prescription premium product aimed at total gut health for the large equine market. Jaguar believes there is a strong and growing need for a personalized, premium product for total gut health in equine athletes, and in December 2017 Jaguar entered into a collaboration agreement with Seed Mena Businessmen Services (SEED) for Equilevia™. Based in the United Arab Emirates, SEED is affiliated with Seed Group, a diversified group of companies under the umbrella of The Private Office of His Royal Highness Sheikh Saeed Bin Ahmed Al Maktoum focused on establishing strategic partnerships with multinational companies from around the globe in an effort to leverage Seed Group's network to support potential business expansion in the Middle East and North Africa region.
Jaguar is managed by a strong team led by founder and CEO Lisa Conte, who is also a member of the board of directors. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, an M.B.A., and an A.B. in Biochemistry from Dartmouth College.
The third quarter of 2017 was the first period for which Jaguar reported consolidated human and animal revenue and financial results, post merger, with two months of human-product revenue. The Company expects to see a significant revenue increase in future quarters as it continues to increase sales and marketing efforts of Mytesi®. The Company reported $2.8 million dollars in gross revenue for Mytesi® during the first 10 months of 2017.
Mr. Alan Stone, Managing Director of WallStreet Research™, commented, "With the introduction of human product revenue, along with an expanding pipeline of animal products, a strong management team, and the ramping up of overall marketing efforts, Jaguar appears well positioned for rapid future growth during 2018 and beyond."
Information on WallStreet Research™ can be found at www.WallStreetResearch.org.
About Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Napo's Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Information on JAGX can be found at www.jaguar.health.
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About WallStreet Research™
WallStreet Research™ ("WSR") is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the micro-cap and small-cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. The firm has offices in Los Angeles, CA; Palm Beach, FL; and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California, Nevada, and Florida. www.WallStreetResearch.org.
The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Commission Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company paid a fee of $5,000 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relations services. For complete disclaimer information, readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding planned, potential follow-on indications for Mytesi®, the Company's expectation that it will generate a significant revenue increase in future quarters as it continues to increase sales and marketing efforts of Mytesi®, and the belief that the Company is well positioned for rapid future growth during 2018 and beyond. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. These forward-looking statements are largely on WSR's and Jaguar's current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, WSR or Jaguar do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact / Source:
Alan Stone, Managing Director, 310-444-3940
Barbara Blake, 415-419-4239
SOURCE: WallStreet Research